COO

Business Context and Reporting Period

Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and six months ended April 30, 2001 (Fiscal Year 2001)
Business Overview: Cooper develops, manufactures, and markets healthcare products through two primary segments: CooperVision (CVI), specializing in contact lenses, and CooperSurgical (CSI), focusing on women's healthcare diagnostic products and surgical instruments.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 10% in the quarter and 15% year-to-date. CVI sales grew 13% (quarter) and 12% (YTD), while CSI sales grew 2% (quarter) and 25% (YTD).
• Profitability: Operating income rose 20% in the quarter and 19% YTD. Diluted EPS increased 23% in the quarter and 25% YTD.
• Segment Performance: CVI's core business grew 17% in the quarter, driven by volume rather than price. International growth was 39% in the quarter, though weakened by foreign currency fluctuations (Pound Sterling, Euro, Canadian Dollar). CSI growth was aided by recent acquisitions (LuMax, Leisegang, MedaSonics).
• Expenses: SGA expenses increased 7% in the quarter, partly due to $700,000 in integration costs at CSI and marketing for new CVI products. R&D expenses rose 33% in the quarter.
• Non-Operating Items: A $719,000 gain was recorded in the first quarter of 2001 from the Quidel/Litmus transaction. Interest expense decreased 29% in the quarter due to lower rates and debt repayments.

Guidance, Outlook, and Risks

• Outlook: Management expects CVI margins to approach 70% of revenue, barring significant mix changes. CSI margins are expected to return to or surpass 56% as acquisitions integrate. The effective tax rate for the full fiscal year 2001 is projected at 32%.
• Liquidity: The company holds $11.9 million in cash and has $32.6 million available under its KeyBank line of credit. Management believes current resources will fund operations, dividends, and smaller acquisitions, though larger deals may require additional financing.
• Dividends: The Board approved an increase in the annual dividend from 8 cents to 10 cents per share.
• Risks & Contingencies:
  • Litigation: Wesley Jessen Corporation (WJ) filed lawsuits in the U.S., England, and France alleging patent infringement regarding CooperVision's Frequency'r'Colors opaque contact lenses. WJ seeks injunctions and damages; Cooper intends to vigorously defend.
  • Foreign Exchange: The company is exposed to currency fluctuations, particularly the Pound Sterling, which impacts both revenue and debt service costs.
  • Acquisition Integration: Risks associated with integrating recent acquisitions (LuMax, Leisegang, MedaSonics, and the subsequent CL-Tinters Oy acquisition).

Investor Verification Checklist

• Patent Litigation Status: Verify the outcome of the Wesley Jessen Corporation lawsuits and the potential impact of injunctions on Frequency'r'Colors sales.
• Acquisition Integration: Monitor the integration progress and margin realization of the LuMax, Leisegang, and CL-Tinters Oy acquisitions.
• Foreign Currency Exposure: Assess the impact of continued weakness in the Pound Sterling and Euro on reported revenue and margins.
• Debt Covenants: Review the KeyBank line of credit terms and the status of the Aspect Vision Care earn-out payments.
• Dividend Sustainability: Confirm that operating cash flows remain sufficient to support the increased dividend rate amidst capital expenditures and acquisition costs.